- Home
- / Intensity Therapeutics
Intensity Therapeutics
Stock Price
$3.1
2024-10-29
Market Capitalization
$42.7 M
2024-10-29
Intensity Therapeutics Summary
Company Summary
- Overview
- Intensity Therapeutics is a biotechnology company that develops intratumoral immunotherapy products. It offers INT230-6 to treat refractory solid tumors by directly injecting a formulation into tumors to kill cancer cells and stimulate the immune system.
- Type
- Public
- Status
- Active
- Founded
- 2012
- HQ
- Shelton, CT, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Ian B. Walters, Chief Medical Officer
James M. Ahlers, Chief Financial Officer
Rebecca Drain, Vice President, Regulatory Affairs and Quality Assurance
LocationsView all
1 location detected
Shelton, CT HQ
United States
1 Enterprise Drive, Suite 430
Intensity Therapeutics Financials
Summary Financials
- Net income (Q1, 2026)
- ($2.4M)
- Cash (Q1, 2026)
- $10.2M
- EBIT (Q1, 2026)
- ($2.5M)
- Enterprise value
- $32.5M